The first meta analyses using DPP4 inhibition in clinical trials show no adverse reactions and even a reduction of cardiovascular risks in T2DM patients treated with DPP4 inhibitors (such as Alogliptin, Vildagliptin, Sitagliptin, Saxagliptin, or Linagliptin; Monami et al., 2013; Avogaro et al., 2014). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.